
Alzheimer’s disease drugs in trial phase III by mechanism of action 2023
As of January 1, 2023, a combined 67 percent of Alzheimer’s disease drugs in clinical phase III of development were disease-modifying therapies, of which 42 percent were small molecule therapies. This statistic illustrates Alzheimer’s disease drugs in phase III of development worldwide, by mechanism of action.